Behrad Derakhshan's most recent trade in Edgewise Therapeutics Inc was a trade of 5,209 Restricted Stock Units done . Disclosure was reported to the exchange on May 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 5,209 | 0 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 5,209 | 22,046 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 01 May 2025 | 1,691 | 20,355 | - | 16.5 | 27,824 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 10,000 | 92,929 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 05 Feb 2025 | 10,000 | 16,837 | - | 30.0 | 300,300 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 05 Feb 2025 | 10,000 | 26,837 | - | 1.9 | 19,300 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 20 Sep 2024 | 42,068 | 57,189 | - | 1.9 | 81,191 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 29.03 per share. | 20 Sep 2024 | 42,068 | 15,121 | - | 29.0 | 1,221,133 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 42,068 | 102,949 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 138,750 | 138,750 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 23,125 | 23,125 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 5,208 | 15,140 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 5,208 | 5,209 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 18.91 per share. | 01 May 2024 | 1,718 | 13,422 | - | 18.9 | 32,487 | Common Stock |
| Edgewise Therapeutics Inc | Derakhshan Behrad | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 07 Feb 2024 | 4,800 | 7,020 | - | 20.0 | 96,209 | Common Stock |
| Edgewise Therapeutics Inc | Derakhshan Behrad | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 4,800 | 145,017 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 07 Feb 2024 | 4,800 | 11,820 | - | 1.9 | 9,264 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 4,600 | 149,817 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 07 Feb 2024 | 4,600 | 11,620 | - | 1.9 | 8,878 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 07 Feb 2024 | 4,600 | 7,020 | - | 20.0 | 92,049 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 07 Feb 2024 | 600 | 7,620 | - | 1.9 | 1,158 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 600 | 154,417 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Derakhshan Behrad | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 07 Feb 2024 | 600 | 7,020 | - | 20 | 12,000 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 5,208 | 10,417 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 5,208 | 8,767 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 8.90 per share. | 01 May 2023 | 1,747 | 7,020 | - | 8.9 | 15,557 | Common Stock |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 15,625 | 15,625 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Behrad Derakhshan | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) |